Joyce M. De Jong-Van Dodewaard
Amersfoort, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
How Does Routine Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Modify the Current Management of Prostate Cancer? A Multidisciplinary View.
Journal: European urology open science
Published: March 16, 2025
The Conundrum of Treating de novo metastatic Hormone-Sensitive Prostate Cancer.
Journal: Scientific reports
Published: June 17, 2024
Feasibility and safety of single-fraction sub-ablative radiotherapy with systemic therapy in colorectal cancer patients with ≤ 10 metastases: A multicenter pilot study (NCT05375708).
Journal: Clinical and translational radiation oncology
Published: May 14, 2024
A sub-pharmacological test dose does not predict individual docetaxel exposure in prostate cancer patients.
Journal: Cancer chemotherapy and pharmacology
Published: January 28, 2024
TripleAiM1: a nationwide registry of de novo metastatic hormone-sensitive prostate cancer with prospective quality-of-life assessment.
Journal: BMJ open
Published: August 29, 2023
Evaluation of the safety and immunological effects of Bacillus Calmette-Guérin in combination with checkpoint inhibitor therapy in a patient with neuroendocrine carcinoma: a case report.
Journal: Journal of medical case reports
Published: December 30, 2022
Clinical judgment of the need for professional mental health care in patients with cancer: a qualitative study among oncologists and nurses.
Journal: Journal of cancer survivorship : research and practice
Published: September 08, 2021
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era.
Journal: British journal of cancer
Published: March 12, 2020
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Journal: Clinical nuclear medicine
Published: March 07, 2017
Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
Journal: Clinical genitourinary cancer
Published: January 11, 2017
A randomised, phase II study of repeated rhenium-188-HEDP combined with docetaxel and prednisone versus docetaxel and prednisone alone in castration-resistant prostate cancer (CRPC) metastatic to bone; the Taxium II trial.
Journal: European journal of nuclear medicine and molecular imaging
Published: November 02, 2016
Last Updated: 09/26/2026